OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians
BackgroundMitochondria appear to play a central role in the induction of an NLRP3 inflammatory response, an immune response critical for the development of gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5 kB circular genome which encodes 36 genes. Therefore mitochondrial ge...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.115-116 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 116 |
---|---|
container_issue | Suppl 2 |
container_start_page | 115 |
container_title | Annals of the rheumatic diseases |
container_volume | 75 |
creator | Merriman, T.R. Gosling, A. Boocock, J. Dalbeth, N. Stamp, L. Stahl, E. Choi, H. Matisoo-Smith, L. |
description | BackgroundMitochondria appear to play a central role in the induction of an NLRP3 inflammatory response, an immune response critical for the development of gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5 kB circular genome which encodes 36 genes. Therefore mitochondrial genetic variation may contribute to susceptibility to gout.ObjectivesThe objective of this study was to test whether mitochondrial genetic variation and copy number among New Zealand Polynesians may be contributing to susceptibility to gout. The Māori and Pacific (Polynesian) populations of New Zealand exhibit a high prevalence of gout (6 and 8%, respectively).Methods439 whole mitochondrial genomes belonging to Māori and Pacific men from New Zealand (327 cases, 112 controls) were sequenced to explore whether mitochondrial DNA (mtDNA) variation may contribute risk to gout. mtDNA copy number variation was also investigated by looking at relative read depth using Next Generation Sequencing data produced from whole genome sequencing and resequencing of urate loci. Quantitative PCR was undertaken for replication in an extended sample set of 540 Polynesian male and female cases and 530 controls.ResultsWithin Polynesia, there is relatively little mitochondrial genetic diversity, with around 96% of those sequenced in this study belonging to the B4a1a and derived sub-lineages. A lineage-specific heteroplasmy in hypervariable region I was found to associate with a greater than three-fold higher risk of gout among the mitochondrial sequenced sample set (e.g. heteroplasmy at position 16179: OR 3.28, P=0.009; heteroplasmy at position 16181: 3.86, P=9x10–5; heteroplasmy at position 16182: 3.43, P=0.005).Quantitative PCR of mtDNA from the 1070 Polynesian gout cases and controls showed that individuals with gout possess less mtDNA, on average than healthy controls. With each unit increase in ΔCt (which reflects a decrease in mtDNA content), there was a 33% increase in gout risk (OR 1.33, P=0.003). The effect was stronger when looking at those participants who possessed urate levels exceeding 0.40 mmol L–1 (n=422, OR 1.69, P=0.0005).ReferencesIt is unclear whether the reduced mtDNA copy number in gout is a result of the gouty pathology directly (i.e. the reduced mtDNA copy number is caused by the inflammatory processes underlying gout) or whether the reduced mtDNA copy number contributes to the risk of gout. The latter possibility is supported by the increase in risk using hyperur |
doi_str_mv | 10.1136/annrheumdis-2016-eular.4476 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901841217</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322512333</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1857-3185d4e61e0a2600338fb37606cb793970d6f090804e1c3d83c0ae26a54c5df43</originalsourceid><addsrcrecordid>eNqVkLFOwzAQhi0EEqXwDpY6p5xj13HEhCooSEWtoLBajuOorlK72MnQjYUX5UlwKQMry53-0__fnT6ERgTGhFB-rZwLa9NvaxuzHAjPTN-qMGas4CdoQBgXaczhFA0AgGas5MU5uohxkyQIIgboebEEMhFfH59PtvN67V0drGrxzDjTWY3fVJKd9Q4rV-OXPmqz62xlW9vt8crjme87bB1e-nbvTLTKxUt01qg2mqvfPkSv93er6UM2X8wep7fzrCJiUmQ01ZoZTgyonKf3qGgqWnDguipKWhZQ8wZKEMAM0bQWVIMyOVcTpid1w-gQjY57d8G_9yZ2cuP74NJJSUoggpGcFMl1c3Tp4GMMppG7YLcq7CUBeYAo_0CUB4jyB6I8QExpfkxX282_gt_EAX2E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901841217</pqid></control><display><type>article</type><title>OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians</title><source>BMJ Journals - NESLi2</source><creator>Merriman, T.R. ; Gosling, A. ; Boocock, J. ; Dalbeth, N. ; Stamp, L. ; Stahl, E. ; Choi, H. ; Matisoo-Smith, L.</creator><creatorcontrib>Merriman, T.R. ; Gosling, A. ; Boocock, J. ; Dalbeth, N. ; Stamp, L. ; Stahl, E. ; Choi, H. ; Matisoo-Smith, L.</creatorcontrib><description>BackgroundMitochondria appear to play a central role in the induction of an NLRP3 inflammatory response, an immune response critical for the development of gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5 kB circular genome which encodes 36 genes. Therefore mitochondrial genetic variation may contribute to susceptibility to gout.ObjectivesThe objective of this study was to test whether mitochondrial genetic variation and copy number among New Zealand Polynesians may be contributing to susceptibility to gout. The Māori and Pacific (Polynesian) populations of New Zealand exhibit a high prevalence of gout (6 and 8%, respectively).Methods439 whole mitochondrial genomes belonging to Māori and Pacific men from New Zealand (327 cases, 112 controls) were sequenced to explore whether mitochondrial DNA (mtDNA) variation may contribute risk to gout. mtDNA copy number variation was also investigated by looking at relative read depth using Next Generation Sequencing data produced from whole genome sequencing and resequencing of urate loci. Quantitative PCR was undertaken for replication in an extended sample set of 540 Polynesian male and female cases and 530 controls.ResultsWithin Polynesia, there is relatively little mitochondrial genetic diversity, with around 96% of those sequenced in this study belonging to the B4a1a and derived sub-lineages. A lineage-specific heteroplasmy in hypervariable region I was found to associate with a greater than three-fold higher risk of gout among the mitochondrial sequenced sample set (e.g. heteroplasmy at position 16179: OR 3.28, P=0.009; heteroplasmy at position 16181: 3.86, P=9x10–5; heteroplasmy at position 16182: 3.43, P=0.005).Quantitative PCR of mtDNA from the 1070 Polynesian gout cases and controls showed that individuals with gout possess less mtDNA, on average than healthy controls. With each unit increase in ΔCt (which reflects a decrease in mtDNA content), there was a 33% increase in gout risk (OR 1.33, P=0.003). The effect was stronger when looking at those participants who possessed urate levels exceeding 0.40 mmol L–1 (n=422, OR 1.69, P=0.0005).ReferencesIt is unclear whether the reduced mtDNA copy number in gout is a result of the gouty pathology directly (i.e. the reduced mtDNA copy number is caused by the inflammatory processes underlying gout) or whether the reduced mtDNA copy number contributes to the risk of gout. The latter possibility is supported by the increase in risk using hyperuricemic controls suggesting that reduced mtDNA copy number plays a role in inflammation. Given emerging research is showing that mitochondria play a central role in the induction of the NLRP3 inflammasome, in particular with the co-localisation of the NLRP3 and ASC sub-units, a process essential for the generation of IL-1β, these observations may be significant. Exploring mitochondrial genetic variation may further elucidate the inflammatory processes underlying gout.AcknowledgementThe New Zealand Health Research Council, Lottery Health New Zealand, Arthritis New Zealand and the National Institute of Health (United States) are thanked for funding this study.Disclosure of InterestT. Merriman Grant/research support from: ArdeaBio, A. Gosling: None declared, J. Boocock: None declared, N. Dalbeth Grant/research support from: AstraZeneca, Fonterra, ArdeaBio, Consultant for: Menarini, Takeda, Teijin, Pfizer, Crealta, Cymabay, L. Stamp: None declared, E. Stahl: None declared, H. Choi: None declared, L. Matisoo-Smith: None declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.4476</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.115-116</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b1857-3185d4e61e0a2600338fb37606cb793970d6f090804e1c3d83c0ae26a54c5df43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/115.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/115.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,781,785,3197,23576,27929,27930,77605,77636</link.rule.ids></links><search><creatorcontrib>Merriman, T.R.</creatorcontrib><creatorcontrib>Gosling, A.</creatorcontrib><creatorcontrib>Boocock, J.</creatorcontrib><creatorcontrib>Dalbeth, N.</creatorcontrib><creatorcontrib>Stamp, L.</creatorcontrib><creatorcontrib>Stahl, E.</creatorcontrib><creatorcontrib>Choi, H.</creatorcontrib><creatorcontrib>Matisoo-Smith, L.</creatorcontrib><title>OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians</title><title>Annals of the rheumatic diseases</title><description>BackgroundMitochondria appear to play a central role in the induction of an NLRP3 inflammatory response, an immune response critical for the development of gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5 kB circular genome which encodes 36 genes. Therefore mitochondrial genetic variation may contribute to susceptibility to gout.ObjectivesThe objective of this study was to test whether mitochondrial genetic variation and copy number among New Zealand Polynesians may be contributing to susceptibility to gout. The Māori and Pacific (Polynesian) populations of New Zealand exhibit a high prevalence of gout (6 and 8%, respectively).Methods439 whole mitochondrial genomes belonging to Māori and Pacific men from New Zealand (327 cases, 112 controls) were sequenced to explore whether mitochondrial DNA (mtDNA) variation may contribute risk to gout. mtDNA copy number variation was also investigated by looking at relative read depth using Next Generation Sequencing data produced from whole genome sequencing and resequencing of urate loci. Quantitative PCR was undertaken for replication in an extended sample set of 540 Polynesian male and female cases and 530 controls.ResultsWithin Polynesia, there is relatively little mitochondrial genetic diversity, with around 96% of those sequenced in this study belonging to the B4a1a and derived sub-lineages. A lineage-specific heteroplasmy in hypervariable region I was found to associate with a greater than three-fold higher risk of gout among the mitochondrial sequenced sample set (e.g. heteroplasmy at position 16179: OR 3.28, P=0.009; heteroplasmy at position 16181: 3.86, P=9x10–5; heteroplasmy at position 16182: 3.43, P=0.005).Quantitative PCR of mtDNA from the 1070 Polynesian gout cases and controls showed that individuals with gout possess less mtDNA, on average than healthy controls. With each unit increase in ΔCt (which reflects a decrease in mtDNA content), there was a 33% increase in gout risk (OR 1.33, P=0.003). The effect was stronger when looking at those participants who possessed urate levels exceeding 0.40 mmol L–1 (n=422, OR 1.69, P=0.0005).ReferencesIt is unclear whether the reduced mtDNA copy number in gout is a result of the gouty pathology directly (i.e. the reduced mtDNA copy number is caused by the inflammatory processes underlying gout) or whether the reduced mtDNA copy number contributes to the risk of gout. The latter possibility is supported by the increase in risk using hyperuricemic controls suggesting that reduced mtDNA copy number plays a role in inflammation. Given emerging research is showing that mitochondria play a central role in the induction of the NLRP3 inflammasome, in particular with the co-localisation of the NLRP3 and ASC sub-units, a process essential for the generation of IL-1β, these observations may be significant. Exploring mitochondrial genetic variation may further elucidate the inflammatory processes underlying gout.AcknowledgementThe New Zealand Health Research Council, Lottery Health New Zealand, Arthritis New Zealand and the National Institute of Health (United States) are thanked for funding this study.Disclosure of InterestT. Merriman Grant/research support from: ArdeaBio, A. Gosling: None declared, J. Boocock: None declared, N. Dalbeth Grant/research support from: AstraZeneca, Fonterra, ArdeaBio, Consultant for: Menarini, Takeda, Teijin, Pfizer, Crealta, Cymabay, L. Stamp: None declared, E. Stahl: None declared, H. Choi: None declared, L. Matisoo-Smith: None declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkLFOwzAQhi0EEqXwDpY6p5xj13HEhCooSEWtoLBajuOorlK72MnQjYUX5UlwKQMry53-0__fnT6ERgTGhFB-rZwLa9NvaxuzHAjPTN-qMGas4CdoQBgXaczhFA0AgGas5MU5uohxkyQIIgboebEEMhFfH59PtvN67V0drGrxzDjTWY3fVJKd9Q4rV-OXPmqz62xlW9vt8crjme87bB1e-nbvTLTKxUt01qg2mqvfPkSv93er6UM2X8wep7fzrCJiUmQ01ZoZTgyonKf3qGgqWnDguipKWhZQ8wZKEMAM0bQWVIMyOVcTpid1w-gQjY57d8G_9yZ2cuP74NJJSUoggpGcFMl1c3Tp4GMMppG7YLcq7CUBeYAo_0CUB4jyB6I8QExpfkxX282_gt_EAX2E</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Merriman, T.R.</creator><creator>Gosling, A.</creator><creator>Boocock, J.</creator><creator>Dalbeth, N.</creator><creator>Stamp, L.</creator><creator>Stahl, E.</creator><creator>Choi, H.</creator><creator>Matisoo-Smith, L.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians</title><author>Merriman, T.R. ; Gosling, A. ; Boocock, J. ; Dalbeth, N. ; Stamp, L. ; Stahl, E. ; Choi, H. ; Matisoo-Smith, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1857-3185d4e61e0a2600338fb37606cb793970d6f090804e1c3d83c0ae26a54c5df43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merriman, T.R.</creatorcontrib><creatorcontrib>Gosling, A.</creatorcontrib><creatorcontrib>Boocock, J.</creatorcontrib><creatorcontrib>Dalbeth, N.</creatorcontrib><creatorcontrib>Stamp, L.</creatorcontrib><creatorcontrib>Stahl, E.</creatorcontrib><creatorcontrib>Choi, H.</creatorcontrib><creatorcontrib>Matisoo-Smith, L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merriman, T.R.</au><au>Gosling, A.</au><au>Boocock, J.</au><au>Dalbeth, N.</au><au>Stamp, L.</au><au>Stahl, E.</au><au>Choi, H.</au><au>Matisoo-Smith, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>115</spage><epage>116</epage><pages>115-116</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundMitochondria appear to play a central role in the induction of an NLRP3 inflammatory response, an immune response critical for the development of gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5 kB circular genome which encodes 36 genes. Therefore mitochondrial genetic variation may contribute to susceptibility to gout.ObjectivesThe objective of this study was to test whether mitochondrial genetic variation and copy number among New Zealand Polynesians may be contributing to susceptibility to gout. The Māori and Pacific (Polynesian) populations of New Zealand exhibit a high prevalence of gout (6 and 8%, respectively).Methods439 whole mitochondrial genomes belonging to Māori and Pacific men from New Zealand (327 cases, 112 controls) were sequenced to explore whether mitochondrial DNA (mtDNA) variation may contribute risk to gout. mtDNA copy number variation was also investigated by looking at relative read depth using Next Generation Sequencing data produced from whole genome sequencing and resequencing of urate loci. Quantitative PCR was undertaken for replication in an extended sample set of 540 Polynesian male and female cases and 530 controls.ResultsWithin Polynesia, there is relatively little mitochondrial genetic diversity, with around 96% of those sequenced in this study belonging to the B4a1a and derived sub-lineages. A lineage-specific heteroplasmy in hypervariable region I was found to associate with a greater than three-fold higher risk of gout among the mitochondrial sequenced sample set (e.g. heteroplasmy at position 16179: OR 3.28, P=0.009; heteroplasmy at position 16181: 3.86, P=9x10–5; heteroplasmy at position 16182: 3.43, P=0.005).Quantitative PCR of mtDNA from the 1070 Polynesian gout cases and controls showed that individuals with gout possess less mtDNA, on average than healthy controls. With each unit increase in ΔCt (which reflects a decrease in mtDNA content), there was a 33% increase in gout risk (OR 1.33, P=0.003). The effect was stronger when looking at those participants who possessed urate levels exceeding 0.40 mmol L–1 (n=422, OR 1.69, P=0.0005).ReferencesIt is unclear whether the reduced mtDNA copy number in gout is a result of the gouty pathology directly (i.e. the reduced mtDNA copy number is caused by the inflammatory processes underlying gout) or whether the reduced mtDNA copy number contributes to the risk of gout. The latter possibility is supported by the increase in risk using hyperuricemic controls suggesting that reduced mtDNA copy number plays a role in inflammation. Given emerging research is showing that mitochondria play a central role in the induction of the NLRP3 inflammasome, in particular with the co-localisation of the NLRP3 and ASC sub-units, a process essential for the generation of IL-1β, these observations may be significant. Exploring mitochondrial genetic variation may further elucidate the inflammatory processes underlying gout.AcknowledgementThe New Zealand Health Research Council, Lottery Health New Zealand, Arthritis New Zealand and the National Institute of Health (United States) are thanked for funding this study.Disclosure of InterestT. Merriman Grant/research support from: ArdeaBio, A. Gosling: None declared, J. Boocock: None declared, N. Dalbeth Grant/research support from: AstraZeneca, Fonterra, ArdeaBio, Consultant for: Menarini, Takeda, Teijin, Pfizer, Crealta, Cymabay, L. Stamp: None declared, E. Stahl: None declared, H. Choi: None declared, L. Matisoo-Smith: None declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.4476</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.115-116 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1901841217 |
source | BMJ Journals - NESLi2 |
title | OP0158 Mitochondrial Genetic Variation and Susceptibility To Gout in Polynesians |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T18%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=OP0158%E2%80%85Mitochondrial%20Genetic%20Variation%20and%20Susceptibility%20To%20Gout%20in%20Polynesians&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Merriman,%20T.R.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=115&rft.epage=116&rft.pages=115-116&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.4476&rft_dat=%3Cproquest_cross%3E4322512333%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901841217&rft_id=info:pmid/&rfr_iscdi=true |